2. Academic Validation
  3. Identification of Potent, Selective, and Peripherally Restricted Serotonin Receptor 2B Antagonists from a High-Throughput Screen

Identification of Potent, Selective, and Peripherally Restricted Serotonin Receptor 2B Antagonists from a High-Throughput Screen

  • Assay Drug Dev Technol. 2023 Apr;21(3):89-96. doi: 10.1089/adt.2022.116.
Aaron M Bender 1 2,  Michael S Valentine 3,  Joshua A Bauer 4 5,  Emily Days 4,  Craig W Lindsley 1 2 5 6,  W David Merryman 3
Affiliations

Affiliations

  • 1 Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Franklin, Tennessee, USA.
  • 2 Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
  • 3 Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA.
  • 4 Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee, USA.
  • 5 Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, USA.
  • 6 Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA.
PMID: 36930852 DOI: 10.1089/adt.2022.116
Abstract

Antagonists of the serotonin receptor 2B (5-HT2B) have shown great promise as therapeutics for the treatment of pulmonary arterial hypertension, valvular heart disease, and related cardiopathies. Herein, we describe a high-throughput screen campaign that led to the identification of highly potent and selective 5-HT2B antagonists. Furthermore, selected compounds were profiled for their predicted ability to cross the blood-brain barrier. Two exemplary compounds, VU0530244 and VU0631019, were predicted to have very limited potential for brain penetration in human subjects, a critical profile for the development of 5-HT2B antagonists devoid of centrally-mediated adverse effects.

Keywords

5-HT2B, pulmonary arterial hypertension; high-throughput screen; serotonin.

Figures
Products